Taking Leqembi is a serious commitment.
The drug is given via infusion every two weeks for 18 monthsand it takes about an hour every time.
The switch is optionalpatients can choose to stick with the current schedule if it works for them.
Illustration by Julie Bang for Verywell Health
Access to Leqembi is tricky, and not everyone will qualify for the drug.
It is most helpful for patients in the early stages of Alzheimers who havemild cognitive impairment.
Research also suggests that keeping up with treatment matters.
Improving access to the drug has been a major goal since its approval.
That decision is expected later this year.
Food and Drug Administration.FDA grants accelerated approval for Alzheimers disease treatment.
National Library of Medicine: DailyMed.Leqembilecanemab injection, solution[drug label].
Food and Drug Administration.Drug trials snapshots: Leqembi.
